Acumen Research and Consulting recently published report titled “Herceptin Biosimilar Market, Share, Analysis Report and Region Forecast, 2022 – 2030”
LOS ANGELIS, Aug. 22, 2022 (GLOBE NEWSWIRE) — , August 22, 2022 (GLOBE NEWSWIRE) – The Global Herceptin Biosimilar Market Size was valued at USD 1,795 Million in 2021 and is predicted to be worth USD 11,287 Million by 2030, with a CAGR of 23.2% from 2022 to 2030.
Breast cancer is among the most common causes among women worldwide. An increase in the incidence of gastric and breast cancer among individuals, particularly women, is a major factor contributing to the growth Herceptin biosimilar market size. In the coming years, there will be numerous opportunities for the global Herceptin biosimilars market shares to expand. This advancement can be attributed to a wide range of factors. Globally, people’s lifestyles have undergone a noticeable shift in recent years. The number of individuals who smoke has also significantly increased. All of these factors have contributed to a growth in the proportion of cancer patients worldwide. This type of situation has resulted in significant market opportunities in the global Herceptin biosimilar market trends.
Herceptin, also known as trastuzumab, is a monoclonal antibody that is being used to treat various cancer patients. Herceptin is a type of immune-targeted treatment that works by inhibiting the living being’s vascular endothelial growth factor. Herceptin biosimilar incorporates the chemotherapy drugs cyclophosphamide and doxorubicin, which are used as a component of a treatment regimen. The rising incidence of breast cancer among people, combined with advancements in the healthcare sector, is influencing the growth of the global market. Besides that, growing R&D activities in the healthcare profession and technological advancements are expected to boost overall industry demand for Herceptin biosimilars market size throughout the projected period.
Request For Free Sample Report @
|Market||Herceptin Biosimilar Market|
|Herceptin Biosimilar Market Size 2021||USD 1,795 Million|
|Herceptin Biosimilar Market Forecast 2030||USD 11,287 Million|
|Herceptin Biosimilar Market CAGR During 2022 – 2030||23.2%|
|Herceptin Biosimilar Market Analysis Period||2018 – 2030|
|Herceptin Biosimilar Market Base Year||2021|
|Herceptin Biosimilar Market Forecast Data||2022 – 2030|
|Segments Covered||By Application, By End-User, And By Region|
|Herceptin Biosimilar Market Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Amgen Inc., Biocon Limited, Merck & Co., Inc., Gedeon Richter Plc, Mabion SA, Roche Holding AG, AryoGen Biopharma, Pfizer Inc., Accord Healthcare Ltd, Genor Biopharma Company Ltd, Mylan N.V, and Samsungbioepis Co., Ltd.|
|Report Coverage||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
Global Herceptin Biosimilar Market Dynamics
Growing development and advancement in the healthcare sector and the increasing implementation of advanced innovation lead to the expansion of the Herceptin biosimilars market growth. Furthermore, higher healthcare applications for anticancer therapy and stimulating sustainable therapeutic interventions in healthcare facilities are propelling the development of the Herceptin biosimilars market value in the coming years. The increasing incidence of malignant tumors such as gastric cancer, breast cancer, and others can be likened to the Herceptin biosimilars market growth. According to the World Health Organization, approximately 2.26 million people have cancer, which leads to the rise of monoclonal antibodies for diagnosis and drives the Herceptin biosimilars market value during the forecast period.
Aside from that, the COVID-19 global epidemic had a significant impact on the Herceptin biosimilars market trends. Due to the COVID-19 disease outbreak, production and inventory chain were hampered by lockdown, causing damage to distribution platforms. Furthermore, COVID-19 is impacting oncology medical intervention, so federal govt regulatory agencies have incorporated some regulations to slow the spread of COVID-19 infectious disease, which is having a negative impact on the development of this market.
Check the detailed table of contents of the report @
The global herceptin biosimilar market is divided into application and end-user, according to Acumen Research and Consulting. In terms of application, the segment has been classified into breast cancer, lymphoma, leukemia, colorectal cancer, and others. In terms of end-user, the industry is categorized into oncology centers, hospital & clinics, and others.
Herceptin Biosimilar Market Regional Outlook
The Herceptin biosimilar market is divided into five continents: Europe, North America, Asia-Pacific, Latin America, and the Middle East and Africa. According to the Herceptin biosimilar market analysis, North America is projected to lead the global market during the forecast period. The rising number of patients affected by breast and gastric cancer, developments and improvements in medical sectors, a rise in government funding and support, and the presence of major main players all contribute to the market’s growth in North America. For example, in 2019, Allergan plc and Amgen Inc. collaborated to release KANJINTI (trastuzumab) for the diagnosis of HER2-overexpressing adjuvant as well as metastatic breast cancer, as well as HER2-overexpressing metastatic gastric or gastro esophageal junction adenocarcinoma. KANJINTI has been approved by the US Food and Drug Administration to treat breast and gastric cancer throughout the United States.
Buy this premium research report –
Herceptin Biosimilar Market Players
Nowadays, prominent players are constantly focusing on launching new products in untapped regions, which is shaping the market for Herceptin biosimilars. To keep their competitive position in the market and ultimately benefit the needs of their customers, businesses operating in the Herceptin biosimilars market are undertaking different strategic projects such as the development of new products, collaborations, and geographical and product portfolio expansion. For example, in December 2019, Mylan and Biocon introduced Ogivri (trastuzumab-dkst), a Trastuzumab Biosimilar, in the United States. Mylan intends to make Ogivri available in 150 mg as well as 420mg doses, rising access to treatment for HER2-positive gastric and breast cancer.
Some of the prominent Herceptin biosimilar market companies are Amgen Inc., Genor Biopharma Company Ltd, Merck & Co., Inc., Mabion SA, Roche Holding AG, Pfizer Inc., Mylan N.V, Biocon Limited, AryoGen Biopharma, Gedeon Richter Plc, Accord Healthcare Ltd, and Samsungbioepis Co,.Ltd.
Browse More Research Topic on Healthcare Sector:
The Pelvic Floor Electric Stimulator Market is expected to grow at a CAGR of around 10.0% from 2020 to 2027 and expected to reach the market value of around USD 365.6 Million by 2027.
The Global Infectious Disease Market is expected to grow at a CAGR of around 5.7% from 2020 to 2027 and expected to reach the market value of around USD 24.5 Billion by 2027.
The Global Virtual Clinical Trials Market is expected to grow at a CAGR of around 5.8% from 2020 to 2027 and expected to reach the market value of around USD 14.5 Billion by 2027.
Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
Mr. Richard Johnson
Acumen Research and Consulting
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.